Summary

The global dysmenorrhea treatment market is on a strong growth trajectory, projected to increase significantly over the next decade. Rising awareness around menstrual health and the increasing prevalence of period-related disorders are driving the need for effective treatment options. The market, valued at US$6.85 Bn in 2025, is expected to reach US$12.6 Bn by 2032, expanding at a robust CAGR of 9.08%.

Market Insights

Dysmenorrhea, or severe menstrual pain, affects a large portion of the global female population, especially adolescents and women in their reproductive years. The condition results from the excessive production of prostaglandins during menstruation, leading to abdominal pain, muscle spasms, and reduced blood flow to the uterus.

Lifestyle shifts, changing dietary habits, and greater health awareness have contributed to a rise in dysmenorrhea cases worldwide. This, in turn, is fueling demand for both over-the-counter and prescription treatment options aimed at providing safe and effective relief.

Market Growth Drivers

• Increasing Prevalence of Dysmenorrhea: A large percentage of adolescent and adult women experience primary or secondary dysmenorrhea. Its widespread occurrence continues to drive demand for medical treatment and pain relief products.

• Higher Health Awareness and Access to Care: As women become more proactive in managing menstrual pain, healthcare consultations and use of therapeutic options are on the rise globally.

• Advances in Treatment Modalities: A wide range of treatment options are now available, including NSAIDs, hormonal therapies, and non-pharmaceutical alternatives such as self-heating patches, which are contributing to improved patient outcomes.

Business Opportunity

The growing focus on menstrual wellness has opened up a range of opportunities for pharmaceutical and consumer health companies. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line treatment for menstrual cramps due to their effectiveness in reducing prostaglandin levels. Products such as ibuprofen, naproxen sodium, and mefenamic acid are widely recommended by healthcare professionals.

Additionally, the demand for innovative, non-invasive, and easy-to-use products is rising, with consumers gravitating towards solutions like transdermal patches and herbal alternatives. Companies investing in R&D, product diversification, and digital outreach are poised to gain a competitive advantage.

Regional Outlook

• North America: The US leads the global dysmenorrhea treatment market, supported by high awareness levels, access to advanced healthcare, and a growing number of product launches.

• Europe: The region is witnessing increased investment in menstrual health solutions. Regulatory support and ongoing clinical trials are fostering new innovations in treatment.

• Asia Pacific: Rising female population, increasing health education, and the emergence of women-focused startups are contributing to strong market growth across countries like India, China, and Japan.

• Middle East & Africa and Latin America: These regions are gradually gaining traction due to improving healthcare infrastructure and awareness campaigns around menstrual health.

Key Players

Leading companies in the dysmenorrhea treatment space include:

• Novartis Pharmaceuticals Corporation

• Merck, Inc.

• Bayer Schering Pharma AG

• Vanita Therapeutics

• Alvogen

• Pfizer, Inc.

• Nua

• Cora

• Roche Laboratories

• Taj Pharmaceuticals, Ltd.

• Sanofi

• Terramedic, Inc.

These companies are actively developing new drugs, expanding distribution networks, and investing in technologies to better serve the growing demand for menstrual pain management solutions.

Recent Developments

• Dr. Reddy's Laboratories Ltd reintroduced its OTC Naproxen Sodium Tablets (220 mg) in the US in August 2021, enhancing consumer access to reliable and affordable pain relief options.

• Nua, a women’s wellness startup, launched Cramp Comfort in December 2020 — a self-heating patch offering up to 8 hours of natural relief from period cramps. This innovation reflects the increasing demand for natural, user-friendly menstrual health solutions.

Market Segmentation

By Diseases

• Primary Dysmenorrhea

• Secondary Dysmenorrhea

• Endometriosis

• Adenomyosis

• Uterine Myomas

• Endometrial Polyps

• Cervical Stenosis

• Obstructive Malformations of the Genital Tract

By Therapeutic Class

• Non-Hormonal Medical Treatment

o Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

§ Non-Selective NSAIDs

§ COX-2 Inhibitors

o Transdermal Glyceryl Trinitrate

o Over-The-Counter (OTC) Medications

• Hormonal Medical Treatment

o Combined Oral Contraceptives

o Progestin Regimens

o Levonorgestrel Intrauterine System (LN-IUS)

• Surgical Options

o Laparoscopy

o Hysterectomy

o Presacral Neurectomy

o Laparoscopic Uterosacral Nerve Ablation (LUNA)

o Intrauterine Device (IUD)

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Dysmenorrhea Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Dysmenorrhea Treatment Market Outlook, 2019 - 2032
3.1. Global Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
3.1.1. Key Highlights
3.1.1.1. Primary Dysmenorrhea
3.1.1.2. Secondary Dysmenorrhea
3.1.1.3. Endometriosis
3.1.1.4. Adenomyosis
3.1.1.5. Uterine Myomas
3.1.1.6. Others
3.2. Global Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
3.2.1. Key Highlights
3.2.1.1. Non-Hormonal Medical Treatment
3.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
3.2.1.3. Non-Selective NSAIDs
3.2.1.4. Cox-2 Inhibitors
3.2.1.5. Transdermal Glyceryl Trinitrate
3.2.1.6. Over The Counter (Otc) Medications
3.2.1.7. Others
3.3. Global Dysmenorrhea Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Dysmenorrhea Treatment Market Outlook, 2019 - 2032
4.1. North America Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
4.1.1. Key Highlights
4.1.1.1. Primary Dysmenorrhea
4.1.1.2. Secondary Dysmenorrhea
4.1.1.3. Endometriosis
4.1.1.4. Adenomyosis
4.1.1.5. Uterine Myomas
4.1.1.6. Others
4.2. North America Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
4.2.1. Key Highlights
4.2.1.1. Non-Hormonal Medical Treatment
4.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
4.2.1.3. Non-Selective NSAIDs
4.2.1.4. Cox-2 Inhibitors
4.2.1.5. Transdermal Glyceryl Trinitrate
4.2.1.6. Over The Counter (Otc) Medications
4.2.1.7. Others
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Dysmenorrhea Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
4.3.1. Key Highlights
4.3.1.1. U.S. Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
4.3.1.2. U.S. Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
4.3.1.3. Canada Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
4.3.1.4. Canada Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Dysmenorrhea Treatment Market Outlook, 2019 - 2032
5.1. Europe Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Primary Dysmenorrhea
5.1.1.2. Secondary Dysmenorrhea
5.1.1.3. Endometriosis
5.1.1.4. Adenomyosis
5.1.1.5. Uterine Myomas
5.1.1.6. Others
5.2. Europe Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Non-Hormonal Medical Treatment
5.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
5.2.1.3. Non-Selective NSAIDs
5.2.1.4. Cox-2 Inhibitors
5.2.1.5. Transdermal Glyceryl Trinitrate
5.2.1.6. Over The Counter (Otc) Medications
5.2.1.7. Others
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Dysmenorrhea Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. Germany Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.2. Germany Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.3. U.K. Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.4. U.K. Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.5. France Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.6. France Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.7. Italy Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.8. Italy Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.9. Turkey Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.10. Turkey Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.11. Russia Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.12. Russia Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.1.13. Rest of Europe Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
5.3.1.14. Rest of Europe Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Dysmenorrhea Treatment Market Outlook, 2019 - 2032
6.1. Asia Pacific Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Primary Dysmenorrhea
6.1.1.2. Secondary Dysmenorrhea
6.1.1.3. Endometriosis
6.1.1.4. Adenomyosis
6.1.1.5. Uterine Myomas
6.1.1.6. Others
6.2. Asia Pacific Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Non-Hormonal Medical Treatment
6.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
6.2.1.3. Non-Selective NSAIDs
6.2.1.4. Cox-2 Inhibitors
6.2.1.5. Transdermal Glyceryl Trinitrate
6.2.1.6. Over The Counter (Otc) Medications
6.2.1.7. Others
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Dysmenorrhea Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. China Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.2. China Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.1.3. Japan Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.4. Japan Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.1.5. South Korea Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.6. South Korea Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.1.7. India Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.8. India Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.1.9. Southeast Asia Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.10. Southeast Asia Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.1.11. Rest of Asia Pacific Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
6.3.1.12. Rest of Asia Pacific Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Dysmenorrhea Treatment Market Outlook, 2019 - 2032
7.1. Latin America Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Primary Dysmenorrhea
7.1.1.2. Secondary Dysmenorrhea
7.1.1.3. Endometriosis
7.1.1.4. Adenomyosis
7.1.1.5. Uterine Myomas
7.1.1.6. Others
7.2. Latin America Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Non-Hormonal Medical Treatment
7.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
7.2.1.3. Non-Selective NSAIDs
7.2.1.4. Cox-2 Inhibitors
7.2.1.5. Transdermal Glyceryl Trinitrate
7.2.1.6. Over The Counter (Otc) Medications
7.2.1.7. Others
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Dysmenorrhea Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. Brazil Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
7.3.1.2. Brazil Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
7.3.1.3. Mexico Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
7.3.1.4. Mexico Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
7.3.1.5. Argentina Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
7.3.1.6. Argentina Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
7.3.1.7. Rest of Latin America Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
7.3.1.8. Rest of Latin America Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Dysmenorrhea Treatment Market Outlook, 2019 - 2032
8.1. Middle East & Africa Dysmenorrhea Treatment Market Outlook, by Diseases, Value (US$ Bn), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Primary Dysmenorrhea
8.1.1.2. Secondary Dysmenorrhea
8.1.1.3. Endometriosis
8.1.1.4. Adenomyosis
8.1.1.5. Uterine Myomas
8.1.1.6. Others
8.2. Middle East & Africa Dysmenorrhea Treatment Market Outlook, by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Non-Hormonal Medical Treatment
8.2.1.2. Non-steroidal anti-inflammatory Drugs (NSAIDS)
8.2.1.3. Non-Selective NSAIDs
8.2.1.4. Cox-2 Inhibitors
8.2.1.5. Transdermal Glyceryl Trinitrate
8.2.1.6. Over The Counter (Otc) Medications
8.2.1.7. Others
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Dysmenorrhea Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. GCC Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
8.3.1.2. GCC Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.3.1.3. South Africa Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
8.3.1.4. South Africa Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.3.1.5. Egypt Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
8.3.1.6. Egypt Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.3.1.7. Nigeria Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
8.3.1.8. Nigeria Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.3.1.9. Rest of Middle East & Africa Dysmenorrhea Treatment Market by Diseases, Value (US$ Bn), 2019 - 2032
8.3.1.10. Rest of Middle East & Africa Dysmenorrhea Treatment Market by Therapeutic Class, Value (US$ Bn), 2019 - 2032
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2025
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Novartis Pharmaceuticals Corporation
9.3.1.1. Company Overview
9.3.1.2. Diseases Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. Merck, Inc.
9.3.2.1. Company Overview
9.3.2.2. Diseases Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. Bayer Schering Pharma AG
9.3.3.1. Company Overview
9.3.3.2. Diseases Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Vanita Therapeutics
9.3.4.1. Company Overview
9.3.4.2. Diseases Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Alvogen
9.3.5.1. Company Overview
9.3.5.2. Diseases Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Pfizer, Inc.
9.3.6.1. Company Overview
9.3.6.2. Diseases Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. Nua
9.3.7.1. Company Overview
9.3.7.2. Diseases Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. Cora
9.3.8.1. Company Overview
9.3.8.2. Diseases Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Roche Laboratories
9.3.9.1. Company Overview
9.3.9.2. Diseases Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Taj Pharmaceuticals, Ltd.
9.3.10.1. Company Overview
9.3.10.2. Diseases Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
9.3.11. Sanofi
9.3.11.1. Company Overview
9.3.11.2. Diseases Portfolio
9.3.11.3. Financial Overview
9.3.11.4. Business Strategies and Development
9.3.12. Terramedic, Inc.
9.3.12.1. Company Overview
9.3.12.2. Diseases Portfolio
9.3.12.3. Financial Overview
9.3.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations